


Cytos Pharmaceuticals, LLC
4364 South Alston Avenue
Durham, North Carolina 27713
Phone: (919) 381-2312

7416 '99 MAY 26 A9 50



11 May 1999

Elizabeth A. Yetley, Ph.D., Director
Office of Special Nutritionals (HFS-450)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 C Street, SW
Washington, DC 20204

Re: Oxavert™
Cytos Pharmaceuticals, LLC
Notification of a Dietary Supplement Structure/Function Claim

Dear Dr. Yetley:

Enclosed please find notice that Cytos Pharmaceuticals, LLC bears a statement on the label of its dietary supplement product, Oxavert™ (L-histidine), as listed in Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act. The enclosed notice is submitted in compliance with 21 CFR §101.93, and an original and two copies of this notification are provided as required.

If you have any questions or need additional information, please do not hesitate to call me at (919) 381-2313. Thank you for your consideration.

Sincerely,

A handwritten signature in black ink, appearing to read "Hugh N. Tucker", written over a horizontal line.

Hugh N. Tucker, Ph.D.
President

Enclosure

97S - 0162

65107

LET 3612

CONFIDENTIAL

**NOTIFICATION OF A DIETARY SUPPLEMENT
STRUCTURE/FUNCTION CLAIM**

11 May 1999

Sponsor: Cytos Pharmaceuticals, LLC

Dietary Supplement: Oxavert™

Prepared by: Cato Research Ltd.
200 Westpark Corporate Center
4364 South Alston Avenue
Durham, North Carolina 27713-2280

**NOTIFICATION OF A DIETARY SUPPLEMENT
STRUCTURE/FUNCTION CLAIM****Administrative Information (Required by 21 CFR §101.93 (a)(2)(i)):**

Manufactured for Cytos Pharmaceuticals, LLC by:

Banner Pharmacaps Inc.

P.O. Box 2210

High Point, NC 27261-2210

Phone: (910) 812-8700

Fax: (910) 812-9091

Distributor:

Cytos Pharmaceuticals, LLC

4364 South Alston Avenue

Durham, North Carolina 27713

Phone: (919) 381-2312

The Text of the Statement That is Being Made (Required by 21 CFR §101.93 (a)(2)(ii)):

“Histidine has been shown to be an excellent quencher of the toxic oxygen species and free radicals that have been associated with cell damage during inflammation, exercise, and stress.”

The Name of the Dietary Supplement That is the Subject of the Statement (Required by 21 CFR §101.93 (a)(2)(iii) and (iv)):

Dietary Supplement Name: L-histidine

Brand Name: Oxavert™

Oxavert™

CERTIFICATION OF INFORMATION

In compliance with 21 CFR §101.93 (a)(3), I certify that the information presented and contained in the notice herein is complete and accurate. Cytos Pharmaceuticals, LLC, the notifying firm, has substantiation that the statement contained in this notice is truthful and not misleading.



Hugh N. Tucker, Ph.D.
President
Cytos Pharmaceuticals, LLC

11/07/1999
Date